Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Aust Endod J ; 49 Suppl 1: 330-338, 2023 Sep.
Article in English | MEDLINE | ID: mdl-36723392

ABSTRACT

Iloprost's anti-inflammatory effects on human dental pulp stem cells (HDPCs) are currently unknown. We hypothesized that iloprost could downregulate the expression of inflammatory-related genes and protein in an inflamed HDPC in vitro model. To induce inflammation, the HDPCs were treated with a cocktail of interleukin-1 beta, interferon-gamma, and tumour necrosis alpha, at a ratio of 1:10:100. Iloprost (10-6  M) was then added or not to the cultures. Interleukin-6 (IL-6) and interleukin-12 (IL-12) mRNA expression were assessed by real-time polymerase chain reaction. IL-6 protein expression was assessed by enzyme-linked immunosorbent assay. The results were analysed using one-way ANOVA or the Kruskal-Wallis test. The cytokine cocktail induced more robust IL-6 expression than LPS treatment. Iloprost slightly, yet significantly, downregulated IL-6 and IL-12 mRNA expression. These findings suggest that iloprost might be used as a beneficial component in vital pulp therapy.


Subject(s)
Epoprostenol , Iloprost , Humans , Iloprost/pharmacology , Iloprost/metabolism , Epoprostenol/metabolism , Epoprostenol/pharmacology , Interleukin-6 , Dental Pulp/metabolism , Interleukin-12/metabolism , Interleukin-12/pharmacology , RNA, Messenger/metabolism , RNA, Messenger/pharmacology , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/metabolism , Cells, Cultured , Lipopolysaccharides/pharmacology , Lipopolysaccharides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL